Back to School: How biopharma can reboot drug development. Access exclusive analysis here

New Cas enzyme can edit RNA, target tau

In Cell, researchers from the Salk Institute for Biological Studies discovered a new RNA-targeting CRISPR enzyme, CRISPR-associated protein 13d (Cas13d), and showed it could be used to edit the transcript of a frontotemporal dementia

Read the full 349 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers